Savior Lifetec Corp.
TTPEX:416720.90
TWD
0.00
(0.00%)
ISIN
TW0004167002
Return %
Stock
S&P 500
1Y
27.92
14.20
3Y
25.40
81.12
5Y
9.15
68.34
Capital Structure
TWD
•
in mil. unless spec.Working Capital
TWD
•
in mil. unless spec.Growth Rates
TWD
•
in mil. unless spec.Quarterly Revenue
TWD
•
in mil. unless spec.Quarterly Earnings Per Share
TWD
•
in mil. unless spec.Quarterly Dividends Per Share
TWD
•
in mil. unless spec.Company Description
- CEO
- Yung-Fa Chen
- Full Time Employees
- 375
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- No. 1, Nanke 6th Road Miaoli Taiwan 744094
- IPO Date
- Dec 21, 2012
- Website
- saviorlifetec.com.tw
- Similar Companies
- Business
- Savior Lifetec Corporation is a specialty injectable pharmaceutical company headquartered in Miaoli County, Taiwan, founded in 1993. The company specializes in the development, production, and supply of sterile active pharmaceutical ingredients (APIs) and finished dosage formulations. Its core product portfolio includes carbapenem generic drugs and injections, notably imipenem and cilastatin, meropenem, and ertapenem antibiotic products. Additionally, the company manufactures and commercializes various injectable drugs such as paliperidone palmitate, cetrorelix and ganirelix acetate, plecanatide, prucalopride succinate, and brinzolamide. Savior Lifetec operates state-of-the-art vertically integrated facilities compliant with stringent regulatory standards from the US, EU, and Japan, supporting sterile crystallization, aseptic dry powder handling, vialing using isolators, and advanced aseptic processing technologies. Recent company developments include strategic leadership changes in 2021 and an expansion into health supplements launched in mid-2023. Savior Lifetec completed an equity buyback program in April 2025, repurchasing 2.19% of shares, reflecting a focus on shareholder value enhancement. The company continues to strengthen its global footprint, with regulatory affairs teams registering its pharmaceutical products in over 80 countries, emphasizing international market penetration. Savior Lifetec's ongoing innovation and research and development activities underscore its commitment to advancing injectable pharmaceutical technologies and broadening its product offerings in specialty pharmaceuticals and health-related sectors. Savior Lifetec serves healthcare providers and pharmaceutical companies globally, producing sterile APIs and finished dosage forms primarily in injectable form. Its manufacturing capabilities, comprehensive quality control systems, and GLP-compliant R&D centers position it as a prominent player in the biotechnology and specialty pharmaceutical industry in Taiwan and internationally. The company’s integration across the pharmaceutical supply chain from API production to finished formulation manufacturing supports its target markets in delivering high-quality injectable therapies to patients worldwide. Savior Lifetec’s recent operational and strategic initiatives demonstrate its focus on growth, innovation, and regulatory compliance within the competitive healthcare sector.